EIDD-1931 New

Data Sheet For research use only. Not for human use.

Cat. No. ：BCP33953CAS No. ：3258-02-4Purity：98%

Size	Price	Stock	Quotation Inquiry
100.00 mg	Get quote	In-stock	Quotation Inquiry
500.00 mg	Get quote	In-stock	Quotation Inquiry
1.00 g	Get quote	In-stock	Quotation Inquiry

Get Quotation Now

Tel: 0086-17754423994 or orders@biochempartner.com

* Required Fields.

Please complete the form below and you will get the price list in 1 minute.

* Required Fields.

Please complete the form below and we will contact you shortly.

* Required Fields.

Please complete the form below and we will contact you shortly.

CAS No.	3258-02-4	Cat. No.	BCP33953
Name	EIDD-1931
Synonyms	N4-Hydroxycytidine;NHC;Beta-d-N4-hydroxycytidine; EIDD 1931; EIDD1931; N4-Hydroxycytidine; β-D-N4-hydroxycytidine; Uridine, 4-oxime; NHC; EIDD-2801-metabolite; EIDD2801-metabolite; EIDD 2801-metabolit;
SMILES	C1=CN(C(=O)N=C1NO)C2C(C(C(O2)CO)O)O
Chemical Name
Formula	C9H13N3O6	M. Wt	259.22
Purity	98%	Storage	Store at 4-8°C
Description	Beta-d-N4-hydroxycytidine is a promising COVID-19 inhibitor. EIDD-1931 has broad spectrum antiviral activity against SARS-CoV-2, MERS-CoV, SARS-CoV, and related zoonotic group 2b or 2c Bat-CoVs, as well as increased potency against a coronavirus bearing resistance mutations to the nucleoside analog inhibitor remdesivir. In mice infected with SARS-CoV or MERS-CoV, both prophylactic and therapeutic administration of EIDD-2801, an orally bioavailable NHC-prodrug (β-D-N4-hydroxycytidine-5'-isopropyl ester), improved pulmonary function, and reduced virus titer and body weight loss. Decreased MERS-CoV yields in vitro and in vivo were associated with increased transition mutation frequency in viral but not host cell RNA, supporting a mechanism of lethal mutagenesis in CoV. The potency of NHC/EIDD-2801 against multiple coronaviruses and oral bioavailability highlight its potential utility as an effective antiviral against SARS-CoV-2 and other future zoonotic coronaviruses.